Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2014, corresponding to fiscal 2015 Q2 and first half. The filing was signed November 19, 2014. Financial statements are unaudited; share and per-share figures reflect the August 2014 1-for-20 reverse split.
Business context
Vistagen is a clinical-stage biopharmaceutical company with no current revenue. Its lead candidate, AV-101, completed Phase 1 development and is being developed for depression and other central nervous system conditions. The company also pursues stem-cell-based drug rescue programs, initially focused on cancer therapies.
Financial results and position
| Metric | Three months ended September 30, 2014 | Six months ended September 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $557,600 | $1,031,200 |
| General and administrative expense | $556,100 | $1,353,300 |
| Operating loss | $1,113,700 | $2,384,500 |
| Net loss | $2,020,900 | $6,574,200 |
| Basic loss per share | $1.58 | $5.24 |
Cash flow: Operating activities used $1,533,400 in the six-month period, compared with $1,316,400 in the prior-year period. Financing activities provided $1,533,400, leaving cash unchanged at zero; cash was also zero at March 31, 2014.
Liquidity and debt: At September 30, total assets were $386,900 and total liabilities were $17,756,100. Current assets were $189,900 versus current liabilities of $6,893,500, a working capital deficit of approximately $6.7 million. The balance sheet reported no cash and cash equivalents. Notes and convertible notes, including accrued interest and net of discounts, totaled approximately $11.2 million across current and non-current classifications. The filing states the company lacked sufficient funds for planned operations, estimating approximately $7.5 million in cash expenditures over the following 12 months.
Margins: Not meaningful because the company reported no revenue. No operating or net margin is presented.
Changes versus prior comparable periods
- Quarterly operating expenses decreased about 8% year over year; R&D fell 17%, while G&A rose 2%. Six-month operating expenses declined about 5%, with R&D down 24% and G&A up 18%.
- Quarterly net loss increased from $1.46 million to $2.02 million. For the six months, net loss rose from $1.27 million to $6.57 million.
- The first-half increase in net loss primarily reflects $2.37 million of debt-extinguishment loss, higher interest expense, and a $425,400 non-cash warrant-liability expense; the prior-year period included a $1.88 million non-cash warrant-liability gain. Debt-discount amortization also increased substantially.
- Operating cash use increased to $1.53 million from $1.32 million, while financing proceeds rose to $1.53 million from $718,500.
Outlook, risks, and unusual items
- Funding and going concern: Management expects continuing losses and negative operating cash flows. It says additional financing is necessary; failure to obtain substantial funding could require reduced, deferred, or discontinued research and development and could threaten the company’s ability to continue as a going concern.
- Financing uncertainty: Autilion AG remained in default on an agreement to invest up to $36 million, and the filing gives no assurance it will fund a material amount. An effective registration statement covered a proposed public offering, but no securities had been sold under it by the filing date. The company estimated it would need about $7.5 million from alternative sources if a material financing did not occur.
- Platinum notes: Platinum agreed to convert approximately $4.2 million of senior secured notes and accrued interest into equity if a qualifying financing closed by the applicable deadline. A public offering meeting the stated threshold could result in Series B preferred stock; the filing anticipated extending the deadline. Conversion could improve liquidity but would dilute existing holders. Completion was not assured.
- Subsequent financing: From October 1 through November 17, the company reported raising $165,000 from unit sales, including 10% convertible notes, common shares, and warrants. This is limited relative to the stated funding need.
- AV-101 outlook: On November 6, 2014, the company signed a letter of intent to enter a CRADA with NIMH for a NIMH-sponsored Phase 2 depression study. It anticipated both starting and completing the study in 2015; this was a planned collaboration, not a completed trial.
- Unusual accounting and capital matters: The quarter included a $1.60 million debt-extinguishment charge related to modifying Platinum notes. The six-month charge for debt extinguishments was $2.37 million. The warrant liability was $3.40 million and is remeasured using significant unobservable inputs, causing potentially volatile non-cash gains or losses. The 1-for-20 reverse split took effect August 14, 2014.
- Management reported effective disclosure controls and procedures and no material change in internal control over financial reporting. The company reported no material legal proceedings.
Important facts for investors to verify
- Whether Vistagen secured the financing needed to cover its estimated $7.5 million of next-12-month cash expenditures, and whether it remained a going concern.
- Whether Autilion made any material investment and whether the proposed public offering closed, including its proceeds, terms, and dilution.
- Whether Platinum’s approximately $4.2 million of senior notes converted to equity, on what terms, and whether the conversion deadline was extended.
- Whether the proposed NIMH CRADA was finalized and the Phase 2 AV-101 study began as anticipated in 2015.
- The company’s cash runway, debt maturities, and ability to meet current liabilities given zero reported cash and a substantial working capital deficit.